Health & Fitness
Wed, November 30, 2011
BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2011 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 6, 2011 at 9:45 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa calendar of events page on the NPS website at [ http://www.npsp.com/events ].
About NPS Pharmaceuticals
NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX (teduglutide) in adult short bowel syndrome (SBS) and NATPARATM (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPSa earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.
